Publications & Events

Top-down mass spectrometric immunoassay for human insulin and its therapeutic analogs, J Proteomics. 2018 Mar 20;175:27-33
Mass spectrometric studies of apolipoprotein proteoforms and their role in lipid metabolism and type 2 diabetes, Proteomes. 2017 Oct 15;5(4). pii: E27. doi: 10.3390/proteomes5040027
Human proteoforms as new targets for clinical mass spectrometry protein tests, Expert Rev Proteomics. 2017 Aug;14(8):691-699.
Mass spectrometry protein tests: Ready for primetime (or not), Expert Rev Proteomics. 2017 Jan;14(1):1-7
Mass spectrometric immunoassays for discovery, screening and quantification of clinically relevant proteoforms, Bioanalysis. 2016 Aug;8(15):1623-1633
Mass spectrometry-based protein assays for in-vitro diagnostic testing, Expert Rev Mol Diagn. 2012 Apr;12(3):235-9.

Next Generation Clinical Diagnostics Assays. CPSA Analytics, May 6-9, 2019, Boston MA.
Next Generation Clinical Diagnostics Assays. CPSA Shanghai, April 10-12, 2019, Shanghai, China.
MS Protein Tests for the Clinical Laboratory. MSACL 2019 USA, April 1-4, Palm Springs, CA
Translating Mass Spectrometry-Based Protein Assays And The Challenging Road Ahead: Post-Translationally Modified Proteins As Biomarker Targets For Clinical MS Protein Tests. 5th EFLM-UEMS European Joint Congress on Laboratory Medicine, October 10-13, 2018, Antalya, Turkey.
Post-Translationally Modified Proteins as Biomarker Targets for Clinical MS Tests. CPSA Analytics, May 7-8, 2018, Boston, MA.
Quantitative Aspects of MALDI-TOF MS for Protein Biomarkers Analysis. CPSA Shanghai, April 18-20, 2018, Shanghai, China.
Mass Spectrometric Studies of Apolipoprotein Proteoforms and their Role in Lipid Metabolism and Type 2 Diabetes. MSACL 2018, USA, January 21-25, Palm Springs, CA.
Translating MS protein assays into the clinic: The challenging road ahead, and the potential of posttranslationally modified proteins as new biomarker targets for clinical MS protein tests. HUPO 2017, September 17-21, Dublin, Ireland.